pdf   xlsx method abbreviations

breast cancer - HR positive, cyclin inhibitor , meta-analysis of study results

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths (OS) 0.77 [0.69, 0.86]< 10%5 studies (5/-)100.0 %lownot evaluable highcrucial-
deaths (OS) (extension) 0.73 [0.59, 0.90]< 10%1 study (1/-)99.9 %NAnot evaluable important-
iDFS 0.93 [0.74, 1.17]< 10%1 study (1/-)73.3 %NAnot evaluable important-
progression or deaths (PFS) 0.53 [0.48, 0.58]< 10%8 studies (8/-)100.0 %lownot evaluable highimportant-
CBR 1.59 [1.36, 1.86]> 10%5 studies (5/-)100.0 %lownot evaluable highnon important-
objective responses (ORR) 1.93 [1.62, 2.31]> 132%7 studies (7/-)100.0 %lownot evaluable highnon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.